US20070042143A1 - Sachet for a pharmaceutical composition - Google Patents
Sachet for a pharmaceutical composition Download PDFInfo
- Publication number
- US20070042143A1 US20070042143A1 US10/553,630 US55363004A US2007042143A1 US 20070042143 A1 US20070042143 A1 US 20070042143A1 US 55363004 A US55363004 A US 55363004A US 2007042143 A1 US2007042143 A1 US 2007042143A1
- Authority
- US
- United States
- Prior art keywords
- sachet
- sachet according
- per unit
- unit area
- weight per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/12—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of paper or cardboard
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
- B32B15/085—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/20—Layered products comprising a layer of metal comprising aluminium or copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/10—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of paper or cardboard
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/20—Properties of the layers or laminate having particular electrical or magnetic properties, e.g. piezoelectric
- B32B2307/21—Anti-static
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/72—Density
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/724—Permeability to gases, adsorption
- B32B2307/7242—Non-permeable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/724—Permeability to gases, adsorption
- B32B2307/7242—Non-permeable
- B32B2307/7246—Water vapor barrier
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/726—Permeability to liquids, absorption
- B32B2307/7265—Non-permeable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2323/00—Polyalkenes
- B32B2323/04—Polyethylene
- B32B2323/046—LDPE, i.e. low density polyethylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/40—Closed containers
- B32B2439/46—Bags
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/80—Medical packaging
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1303—Paper containing [e.g., paperboard, cardboard, fiberboard, etc.]
Definitions
- the present invention concerns a sachet for a pharmaceutical composition.
- Oral pharmaceutical formulations comprising mesalazine are known, which are either tablets or granulate.
- Granulate may be packed in sachets.
- a “sachet” will refer to an envelope or bag for a granulate, while “granulate” refers to particles, granulate or spheronised particles.
- sachets tend to suffer from the draw back of complicated manufacturing methods or high production costs.
- a sachet should preferably be easy to open without the use of scissors.
- Static electricity may build up between certain granulate types and sachets. This is dependent of the type of granulate as well as the type of sachet. If static electricity is present, it tends to be difficult to pour granulate from the sachet.
- granulate in a sachet may be sensitive to degradation by light, humidity and/or air. This is also dependent of the type of sachet as well as the type of granulate.
- mealazine also encompasses pharmaceutically acceptable salts and esters thereof, such as those mentioned in WO 97/23199 p. 15, l. 17- p. 6, l. 12, as well as prodrugs, such as balsalazide.
- the formulation to be stored in a sachet according to the invention, is preferably in the form of a particulate material, e.g. granulate, spheres, pellets, particles, preferably granulate.
- the present sachet may be used for any pharmaceutical formulation, but is especially suitable for storing pharmaceuticals comprising sensitive compounds such as mesalazine.
- the present invention concerns a sachet, comprising the layers:
- bonding layer preferably an adhesive such as polyethylene
- barrier layer preferably aluminium foil
- sealing layer preferably low density polyethylene.
- a sachet for a product containing mesalazine should therefore preferably provide a barrier to humidity, atmospheric air and light.
- the sachet should also be easy to open for a patient, preferably without the use of additional tools, such as scissors. It has been a problem to provide a sachet with the necessary barrier properties without sacrificing the possibility of tearing open the sachet with human fingers. Further, existing sachets tend to suffer from the build up of static electricity.
- a sachet should be easy to manufacture, easy to fill, easy to empty, and have an appealing look to improve patient compliance.
- This aspect provides a sachet giving long storage stability for a pharmaceutical composition contained therein, e.g. where the active pharmaceutical ingredient is mesalazine. Further, the sachet is easy to tear and static electricity is eliminated, providing for a sachet which may be emptied completely for its contents.
- the combination of the sachet and the oral formulation according to the present invention provides for little build up of static electricity.
- the outer paper i) has in a preferred embodiment a weight per unit area of 10-100 g/m 2 , preferably 30-70 g/m 2 , more preferred 40-60 g/m 2 , most preferred 50 g/m 2 .
- Paper having a weight per unit area outside the range of 10-100 g/m 2 are hardly suitable in industrial manufacturing of sachets. Paper having a weight per unit area below about 30-40 g/cm 2 tend to break in manufacturing equipment for sachets. For paper having a weight per unit area above about 60-70 g/cm 2 it is difficult to shape the material to sachets. Optimal results have been achieved with a weight per unit area above of about 50 g/cm 2 .
- the bonding layer ii) preferably has a weight per unit area of 6-20 g/m 2 , preferably 9-18 g/m 2 , more preferred 12-15 g/m 2 . If a very thin layer is used, it usually necessitate the use of expensive special polymers to achieve an appropriate coverage. If a thick layer is applied, it inherently more expensive and hard to avoid an uneven layer.
- the barrier layer iii) preferably has a thickness of 6-30 ⁇ m, more preferred 7-25 ⁇ m, preferably 9-25 ⁇ m, more preferred 8-20 ⁇ m, preferably 9-15 ⁇ m, more preferred 12 ⁇ m.
- sealing layer iv) has a thickness of 15-50 ⁇ m. If a very thin layer is applied, it has a tendency not to cover the surface completely. If a very thick layer is applied, it is hard to weld through, and any heating applied may not warm evenly.
- the sealing layer iv) preferably has a weight per unit area of 10-100 g/m 2 , more preferred 15-75 g/m 2 , preferably 20-50 g/m 2 , more preferably 30-40 g/m 2 , most preferred 35 g/m 2 .
- the present invention concerns the use of the sachet for a pharmaceutical composition according to the invention.
- the sachet has proven suitable for storing the pharmaceutical compositions according to the invention.
- the present invention concerns the use of the sachet for medical purposes.
- a sachet according to the present sachet is especially suitable for a pharmaceutical formulation comprising mesalazine or a pharmaceutically acceptable salt thereof.
- the present sachet has a remarkably low tendency to build up static electricity. This has formerly especially been a problem with mesalazine granulate.
- mesalazine product may be mentioned granulate obtainable according to the patent application
- mesalazine as the active ingredient in granulate in the present sachet, but also relates to other active ingredients, such as the ingredients mentioned in WO 00/44353, p. 12-16.
- excipients may be comprised in the composition according to the invention, such as fillers, disintegrants, pH adjusters, or surfactants.
- excipients are well known from the literature, see e.g. WO 00/44353, p. 16-20, for a number of suitable excipients.
- excipients are hygroscopic. As an example of such excipient povidone may be mentioned. If an active ingredient is to be formulated with a hygroscopic excipient, the need for a suitable sachet is emphasized. The present sachet is suitable for being used for pharmaceuticals comprising at least one hygroscopic excipient.
- the material of a sachet had the following composition: Paper, claycoated 50 g/m 2 Polyethylene, low density 12 g/m 2 Aluminium foil 12 ⁇ m Polyethylene, low density 35 g/m 2
- g/m 2 PE corresponds to 13 ⁇ m
- 35 g/m 2 PE corresponds to 38 ⁇ m.
- the material had a grammage of 129 g/m 2 .
- the permeability to water vapour was ⁇ 0.05 g/m 2 , 24 h, 25° C., 75% RH, and to O 2 ⁇ 0.05 ml/m 2 , 24 h, atm, 23° C., 75% RH.
- the sachets were folded around the filling tube of a filling/sealing station, such that the paper was on the outside of the sachet, and then sealed lengthwise, with a low density polyethylene as a sealing layer. After forming the cross seal at the bottom the sachet is filled with granulates, and then sealed again at the top and finally cut.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Laminated Bodies (AREA)
- Wrappers (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/553,630 US20070042143A1 (en) | 2003-04-23 | 2004-04-22 | Sachet for a pharmaceutical composition |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46464903P | 2003-04-23 | 2003-04-23 | |
DKPA200300612 | 2003-04-23 | ||
DKPA200300612 | 2003-04-23 | ||
EP20030388023 EP1470819A1 (en) | 2003-04-23 | 2003-04-23 | High drug load mesalazine sachet |
EP03388023.8 | 2003-04-23 | ||
PCT/EP2004/004280 WO2004093883A2 (en) | 2003-04-23 | 2004-04-22 | Sachet for a pharmaceutical composition |
US10/553,630 US20070042143A1 (en) | 2003-04-23 | 2004-04-22 | Sachet for a pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070042143A1 true US20070042143A1 (en) | 2007-02-22 |
Family
ID=36655488
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/553,630 Abandoned US20070042143A1 (en) | 2003-04-23 | 2004-04-22 | Sachet for a pharmaceutical composition |
US10/553,629 Active 2027-01-06 US8858992B2 (en) | 2003-04-23 | 2004-04-23 | High drug load mesalazine sachet |
US14/483,695 Expired - Lifetime US9402815B2 (en) | 2003-04-23 | 2014-09-11 | High drug load mesalazine sachet |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/553,629 Active 2027-01-06 US8858992B2 (en) | 2003-04-23 | 2004-04-23 | High drug load mesalazine sachet |
US14/483,695 Expired - Lifetime US9402815B2 (en) | 2003-04-23 | 2014-09-11 | High drug load mesalazine sachet |
Country Status (20)
Country | Link |
---|---|
US (3) | US20070042143A1 (ko) |
EP (3) | EP1615619A2 (ko) |
JP (4) | JP2007523664A (ko) |
KR (1) | KR100849966B1 (ko) |
CN (1) | CN1777430B (ko) |
AU (1) | AU2004231316B2 (ko) |
CA (2) | CA2520197A1 (ko) |
CY (1) | CY1115560T1 (ko) |
DK (1) | DK1615648T3 (ko) |
ES (1) | ES2486245T3 (ko) |
HK (2) | HK1083312A1 (ko) |
IL (1) | IL170978A (ko) |
MX (1) | MXPA05011308A (ko) |
NO (1) | NO335375B1 (ko) |
NZ (1) | NZ542591A (ko) |
PL (1) | PL1615648T3 (ko) |
PT (1) | PT1615648E (ko) |
RU (2) | RU2547552C2 (ko) |
SI (1) | SI1615648T1 (ko) |
WO (2) | WO2004093883A2 (ko) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8282955B2 (en) | 2001-10-15 | 2012-10-09 | Ferring B.V. | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease |
WO2004093883A2 (en) | 2003-04-23 | 2004-11-04 | Ferring B.V. | Sachet for a pharmaceutical composition |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US7951436B2 (en) | 2006-08-14 | 2011-05-31 | Frito-Lay North America, Inc. | Environmentally-friendly multi-layer flexible film having barrier properties |
US7943218B2 (en) * | 2006-08-14 | 2011-05-17 | Frito-Lay North America, Inc. | Environmentally-friendly multi-layer flexible film having barrier properties |
US7645801B2 (en) | 2007-01-29 | 2010-01-12 | Alaven Pharmaceutical Llc | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
US20090169622A1 (en) * | 2007-12-27 | 2009-07-02 | Roxane Laboratories, Inc. | Delayed-release oral pharmaceutical composition for treatment of colonic disorders |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
WO2009118761A2 (en) * | 2008-03-24 | 2009-10-01 | Bhandari Mohan Harakchand | Metallized paper based lidding material for blister packaging & process thereof |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
ES2732453T3 (es) | 2008-07-01 | 2019-11-22 | Curemark Llc | Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
NZ592049A (en) * | 2008-10-03 | 2012-11-30 | Falk Pharma Gmbh | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
GB2480772B (en) | 2009-01-06 | 2013-10-16 | Curelon Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus |
EP2373693A4 (en) | 2009-01-06 | 2012-04-25 | Curelon Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
ES2556137T3 (es) * | 2010-09-10 | 2016-01-13 | Pharmazell Gmbh | Procedimiento para la preparación de ácido 5-aminosalicílico cristalino |
WO2012145651A2 (en) | 2011-04-21 | 2012-10-26 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
US9040120B2 (en) | 2011-08-05 | 2015-05-26 | Frito-Lay North America, Inc. | Inorganic nanocoating primed organic film |
US9267011B2 (en) | 2012-03-20 | 2016-02-23 | Frito-Lay North America, Inc. | Composition and method for making a cavitated bio-based film |
US9162421B2 (en) | 2012-04-25 | 2015-10-20 | Frito-Lay North America, Inc. | Film with compostable heat seal layer |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
CN104395493B (zh) | 2012-06-23 | 2017-08-25 | 福瑞托-雷北美有限公司 | 超薄无机氧化物涂层在包装上的沉积 |
US9090021B2 (en) | 2012-08-02 | 2015-07-28 | Frito-Lay North America, Inc. | Ultrasonic sealing of packages |
US9149980B2 (en) | 2012-08-02 | 2015-10-06 | Frito-Lay North America, Inc. | Ultrasonic sealing of packages |
CN102784154B (zh) * | 2012-09-01 | 2013-10-09 | 朱文军 | 一种美沙拉嗪肠溶片及其制备方法 |
ES2799888T3 (es) * | 2014-04-17 | 2020-12-22 | Athena Pharmaceutiques Sas | Procedimiento para preparación de composición de mesalamina y composición de mesalamina del mismo |
EP3154523B1 (en) * | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
EP3162362A1 (de) | 2015-10-30 | 2017-05-03 | Dr. Falk Pharma Gmbh | Optimierte mesalazinhaltige hochdosistablette |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
JP7349428B2 (ja) * | 2017-12-20 | 2023-09-22 | フラメル アイルランド リミテッド | 改善された安定性を有するパッケージされた修飾放出ガンマ-ヒドロキシブチラート製剤 |
TR201722852A2 (tr) | 2017-12-29 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
WO2022129003A1 (en) | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Multiparticulate solid oral dosage form comprising statin and vitamin e |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4085244A (en) * | 1976-02-10 | 1978-04-18 | Champion International Corporation | Balanced orientated flexible packaging composite |
US4360550A (en) * | 1979-09-12 | 1982-11-23 | Toyo Kagaku Kabushiki Kaisha | Composite packing film and packing bag made of the same |
US4418841A (en) * | 1982-11-23 | 1983-12-06 | American Can Company | Multiple layer flexible sheet structure |
US4489112A (en) * | 1983-03-28 | 1984-12-18 | Ex-Cell-O Corporation | Laminated paperboard container with absorption resistance means, and blank for constructing same |
US4629657A (en) * | 1982-12-13 | 1986-12-16 | Enron Chemical Company | Biaxially oriented polypropylene film construction for special lamination |
US4693395A (en) * | 1984-12-28 | 1987-09-15 | Colgate-Palmolive Company | Ethylene propylene copolymer in a substrate and collapsible dispensing container made therefrom |
US4702905A (en) * | 1985-08-30 | 1987-10-27 | Colgate-Palmolive Company | Packaged dental cream |
US4705680A (en) * | 1986-01-22 | 1987-11-10 | Colgate-Palmolive Company | Stable dental cream in polyethylene or polypropylene container |
US4867977A (en) * | 1986-07-01 | 1989-09-19 | Sandoz, Ltd. | Calcium salts |
US5091241A (en) * | 1988-12-05 | 1992-02-25 | Lang Theodore J | Film laminate with easy to tear |
US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
US5474818A (en) * | 1992-05-15 | 1995-12-12 | International Paper | Flexible container with nonstick interior |
US5695839A (en) * | 1990-11-14 | 1997-12-09 | Dai Nippon Printing Co., Ltd. | Composite container having barrier property |
US6150004A (en) * | 1994-07-14 | 2000-11-21 | Kyodo Printing Co., Ltd. | Antimicrobial laminate and bag, container, and shaped cup using same |
US6199698B1 (en) * | 1999-12-03 | 2001-03-13 | Alusuisse Technology & Management, Ltd. | Pharmaceutical packaging with separation means |
US20020034541A1 (en) * | 2000-07-14 | 2002-03-21 | Roberto Valducci | Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
US20020177579A1 (en) * | 2000-11-06 | 2002-11-28 | Larry Augsburger | Extended release formulation of water-soluble drugs |
US6537680B1 (en) * | 1998-09-03 | 2003-03-25 | Stora Kopparbergs Bergslags Aktiebolag (Publ) | Paper or paperboard laminate and method to produce such a laminate |
US6773720B1 (en) * | 1999-06-14 | 2004-08-10 | Cosmo S.P.A. | Mesalazine controlled release oral pharmaceutical compositions |
US6916516B1 (en) * | 1998-02-26 | 2005-07-12 | Alcan Technology & Management Ltd. | Packing material |
US7025205B2 (en) * | 2002-06-26 | 2006-04-11 | Aventis Pharma Limited | Method and packaging for pressurized containers |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4638131B1 (ko) * | 1966-06-22 | 1971-11-10 | ||
US4960765A (en) * | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
WO1981002671A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
JPS6048484B2 (ja) | 1980-05-20 | 1985-10-28 | アルザ・コ−ポレ−シヨン | 拡散性活性剤デイスペンサ− |
JPS5758631A (en) | 1980-09-24 | 1982-04-08 | Toyo Jozo Co Ltd | Coating composition |
ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
DE3151196A1 (de) * | 1981-12-23 | 1983-06-30 | Kurt Heinz Prof. Dr. 7800 Freiburg Bauer | Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen |
SE457505B (sv) | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
NL8502178A (nl) | 1984-08-16 | 1986-03-17 | Sandoz Ag | Nieuwe farmaceutische preparaten. |
US4720473A (en) * | 1986-03-10 | 1988-01-19 | Cri International, Inc. | Production of improved catalyst-type particles using length and density grading |
US5254347A (en) * | 1988-03-31 | 1993-10-19 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation and method for producing the same |
US5484605A (en) * | 1988-11-25 | 1996-01-16 | Henning Berlin Gmbh Chemie-Und Pharmawerk | Agent for treating chronically inflammatory intestinal diseases |
GB8913889D0 (en) * | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
GB2253346A (en) * | 1991-02-22 | 1992-09-09 | John Rhodes | Delayed release oral dosage forms for treatment of intestinal disorders |
GB2256587A (en) | 1991-06-11 | 1992-12-16 | American Cyanamid Co | Acetazolamide in sustained release form |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
JP2607422B2 (ja) * | 1992-09-08 | 1997-05-07 | 呉羽化学工業株式会社 | 内服用吸着剤の分包包装体及びその製造方法 |
JPH0827133B2 (ja) * | 1993-07-13 | 1996-03-21 | 不二パウダル株式会社 | 湿潤粉粒体の処理装置 |
US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
JPH0826977A (ja) | 1994-07-19 | 1996-01-30 | Tanabe Seiyaku Co Ltd | 溶出制御型経口製剤 |
IT1277663B1 (it) * | 1995-09-28 | 1997-11-11 | Crinos Industria Farmaco | Sospensioni acquose stabili di mesalazina per uso topico |
ES2149733T5 (es) * | 1995-12-21 | 2008-05-01 | Farmaceutisk Laboratorium Ferring A/S | Composicion farmaceutica oral de liberacion modificada que contiene 5-asa y metodo para el tratamiento de enfermedades intestinales. |
US6004581A (en) * | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
IL118932A0 (en) | 1996-07-24 | 1996-10-31 | Dexcel Ltd | Controlled release tablets |
JP2002511774A (ja) | 1996-07-28 | 2002-04-16 | バイオセンス・インコーポレイテッド | 電磁的心臓生体刺激法 |
AU5775398A (en) | 1996-12-17 | 1998-07-15 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
US6194465B1 (en) | 1998-05-19 | 2001-02-27 | Centaur Pharmaceuticals, Inc. | Benzamide therapeutics for the treatment of inflammatory bowel disease |
CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
IT1303753B1 (it) * | 1998-11-13 | 2001-02-23 | Ct Lab Farm Srl | Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici. |
PT1146862E (pt) * | 1999-01-29 | 2003-09-30 | Disphar Int Bv | Composicoes farmaceuticas |
JP2001055322A (ja) | 1999-08-18 | 2001-02-27 | Tanabe Seiyaku Co Ltd | パルス放出型製剤 |
JP4439629B2 (ja) * | 1999-09-14 | 2010-03-24 | 久光製薬株式会社 | 包装用袋体 |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
IT1318376B1 (it) | 2000-03-07 | 2003-08-25 | Pharmatec Internat S R L | Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo. |
DE10013030A1 (de) | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Verwendung eines Copolymers zur Herstellung einer Arzneiform zur Therapie von Colitis ulcerosa und verwendungsgemäße Arzneiform |
WO2002017887A1 (de) * | 2000-08-29 | 2002-03-07 | Mepha Ag | Arzneimittel zur behandlung von darmerkrankungen |
PT1441700E (pt) * | 2001-10-15 | 2007-10-29 | Ferring Bv | Método para a preparação de uma composição compreendendo ácido 5-aminosalicílico para uso em tratamento de colites ulcerosas ou da doença de crohn |
US8282955B2 (en) * | 2001-10-15 | 2012-10-09 | Ferring B.V. | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease |
AU2003288182A1 (en) * | 2002-11-26 | 2004-06-18 | Universiteit Gent | Process and apparatus for continuous wet granulation of power material |
WO2004093883A2 (en) | 2003-04-23 | 2004-11-04 | Ferring B.V. | Sachet for a pharmaceutical composition |
EP1547601A1 (en) * | 2003-12-23 | 2005-06-29 | Ferring B.V. | Coating method |
CA2678990A1 (en) * | 2007-02-22 | 2008-08-28 | Ajinomoto Co., Inc. | Method for purifying 4-hydroxyisoleucine |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
-
2004
- 2004-04-22 WO PCT/EP2004/004280 patent/WO2004093883A2/en active Application Filing
- 2004-04-22 US US10/553,630 patent/US20070042143A1/en not_active Abandoned
- 2004-04-22 CA CA002520197A patent/CA2520197A1/en not_active Abandoned
- 2004-04-22 JP JP2006505232A patent/JP2007523664A/ja active Pending
- 2004-04-22 EP EP04728807A patent/EP1615619A2/en not_active Withdrawn
- 2004-04-23 PT PT47290507T patent/PT1615648E/pt unknown
- 2004-04-23 JP JP2006505237A patent/JP4753864B2/ja not_active Expired - Lifetime
- 2004-04-23 DK DK04729050.7T patent/DK1615648T3/da active
- 2004-04-23 MX MXPA05011308A patent/MXPA05011308A/es active IP Right Grant
- 2004-04-23 CA CA2520026A patent/CA2520026C/en not_active Expired - Lifetime
- 2004-04-23 KR KR1020057020069A patent/KR100849966B1/ko active IP Right Grant
- 2004-04-23 RU RU2009111609/15A patent/RU2547552C2/ru active
- 2004-04-23 CN CN2004800107906A patent/CN1777430B/zh not_active Expired - Lifetime
- 2004-04-23 WO PCT/EP2004/004297 patent/WO2004093884A2/en active Application Filing
- 2004-04-23 EP EP04729050.7A patent/EP1615648B1/en not_active Expired - Lifetime
- 2004-04-23 EP EP14163036.8A patent/EP2756844A1/en not_active Withdrawn
- 2004-04-23 NZ NZ542591A patent/NZ542591A/en unknown
- 2004-04-23 US US10/553,629 patent/US8858992B2/en active Active
- 2004-04-23 SI SI200432177T patent/SI1615648T1/sl unknown
- 2004-04-23 AU AU2004231316A patent/AU2004231316B2/en not_active Expired
- 2004-04-23 ES ES04729050.7T patent/ES2486245T3/es not_active Expired - Lifetime
- 2004-04-23 RU RU2005131492/15A patent/RU2005131492A/ru unknown
- 2004-04-23 PL PL04729050T patent/PL1615648T3/pl unknown
-
2005
- 2005-09-19 IL IL170978A patent/IL170978A/en active IP Right Grant
- 2005-11-23 NO NO20055534A patent/NO335375B1/no unknown
-
2006
- 2006-04-26 HK HK06104975.5A patent/HK1083312A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 JP JP2009278169A patent/JP2010090146A/ja active Pending
-
2010
- 2010-02-26 JP JP2010041157A patent/JP2010179109A/ja not_active Withdrawn
-
2014
- 2014-08-04 CY CY20141100596T patent/CY1115560T1/el unknown
- 2014-09-11 US US14/483,695 patent/US9402815B2/en not_active Expired - Lifetime
- 2014-12-09 HK HK14112393.2A patent/HK1198917A1/xx unknown
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4085244A (en) * | 1976-02-10 | 1978-04-18 | Champion International Corporation | Balanced orientated flexible packaging composite |
US4360550A (en) * | 1979-09-12 | 1982-11-23 | Toyo Kagaku Kabushiki Kaisha | Composite packing film and packing bag made of the same |
US4418841A (en) * | 1982-11-23 | 1983-12-06 | American Can Company | Multiple layer flexible sheet structure |
US4629657A (en) * | 1982-12-13 | 1986-12-16 | Enron Chemical Company | Biaxially oriented polypropylene film construction for special lamination |
US4489112A (en) * | 1983-03-28 | 1984-12-18 | Ex-Cell-O Corporation | Laminated paperboard container with absorption resistance means, and blank for constructing same |
US4693395A (en) * | 1984-12-28 | 1987-09-15 | Colgate-Palmolive Company | Ethylene propylene copolymer in a substrate and collapsible dispensing container made therefrom |
US4702905A (en) * | 1985-08-30 | 1987-10-27 | Colgate-Palmolive Company | Packaged dental cream |
US4705680A (en) * | 1986-01-22 | 1987-11-10 | Colgate-Palmolive Company | Stable dental cream in polyethylene or polypropylene container |
US4867977A (en) * | 1986-07-01 | 1989-09-19 | Sandoz, Ltd. | Calcium salts |
US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
US5091241A (en) * | 1988-12-05 | 1992-02-25 | Lang Theodore J | Film laminate with easy to tear |
US5695839A (en) * | 1990-11-14 | 1997-12-09 | Dai Nippon Printing Co., Ltd. | Composite container having barrier property |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
US5474818A (en) * | 1992-05-15 | 1995-12-12 | International Paper | Flexible container with nonstick interior |
US6150004A (en) * | 1994-07-14 | 2000-11-21 | Kyodo Printing Co., Ltd. | Antimicrobial laminate and bag, container, and shaped cup using same |
US6916516B1 (en) * | 1998-02-26 | 2005-07-12 | Alcan Technology & Management Ltd. | Packing material |
US6537680B1 (en) * | 1998-09-03 | 2003-03-25 | Stora Kopparbergs Bergslags Aktiebolag (Publ) | Paper or paperboard laminate and method to produce such a laminate |
US6773720B1 (en) * | 1999-06-14 | 2004-08-10 | Cosmo S.P.A. | Mesalazine controlled release oral pharmaceutical compositions |
US6199698B1 (en) * | 1999-12-03 | 2001-03-13 | Alusuisse Technology & Management, Ltd. | Pharmaceutical packaging with separation means |
US20020034541A1 (en) * | 2000-07-14 | 2002-03-21 | Roberto Valducci | Oral solid pharmaceutical formulations with pH-dependent multiphasic release |
US20020177579A1 (en) * | 2000-11-06 | 2002-11-28 | Larry Augsburger | Extended release formulation of water-soluble drugs |
US7025205B2 (en) * | 2002-06-26 | 2006-04-11 | Aventis Pharma Limited | Method and packaging for pressurized containers |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070042143A1 (en) | Sachet for a pharmaceutical composition | |
JP5936542B2 (ja) | 包装体 | |
ES2381507T3 (es) | Envase medicinal | |
JP5190159B1 (ja) | 医薬 | |
JP3906485B1 (ja) | 薬物包装体 | |
KR101445671B1 (ko) | 피복 고형 제제 | |
CA3082201C (en) | Pouch-type orally dissolving films with high active ingredient concentration | |
KR20200021481A (ko) | 의약품 | |
TW201034688A (en) | Solid coated preparation | |
US5846904A (en) | Soil fumigant preparations | |
WO2020213517A1 (ja) | ブリスター容器用積層体 | |
JP2007185490A (ja) | 薬物包装体 | |
JP2016222714A (ja) | 医薬 | |
JP2021152057A (ja) | 医薬 | |
EP2678006B1 (en) | Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate | |
JP2021147086A (ja) | 包装体 | |
JP2013224285A (ja) | 医薬 | |
KR101125087B1 (ko) | 약물 포장체 | |
JP2014034574A (ja) | 医薬 | |
JP2019043880A (ja) | 医薬組成物 | |
JP2018062524A (ja) | 医薬 | |
EP4295836A1 (en) | Sachet comprising a liquid suspension of a sevelamer salt | |
JP2023005155A (ja) | 歯磨剤組成物 | |
WO2020178878A1 (ja) | 医薬組成物 | |
JP2000084041A (ja) | パップ剤の保存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FERRING B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WIDERSTROM, CARIN;REEL/FRAME:018229/0039 Effective date: 20051031 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |